Robert Paarlberg has more than 35 years pharmaceutical industry experience in US and international regulatory affairs. Previous work experience included The Upjohn Company, Pharmacia and UCB.
In 2010 Mr. Paarlberg founded Paarlberg & Associates LLC, a consultancy specializing in global clinical trial disclosure strategy and operations, regulatory policy and regulatory intelligence.
Robert is current chair of the Drug Information Association's (DIA) Clinical Trial Disclosure Community. Robert led the Drug Information Association (DIA) 2011 clinical trial disclosure workshop "The Evolving Clinical Trial Disclosure Landscape"; program co-chair of DIA's 2013 conference "Clinical Trial Disclosure: Towards a More Transparent World"; and, is program chair of DIA's 2015 conference "Clinical Trial Disclosure & Transparency - The Expanding Global Environment". In 2015 Mr. Paarlberg received DIA's Excellence in Service Award.
Forst HT, Paarlberg R. Outcome Measures in Study Registries: The Need for a Consistent Approach. Drug Information Journal. 2012; 46:485-492.
Forst HT, Paarlberg R. FDAAA Basic Results Reporting: First Experience and Challenges. Drug Information Journal. 2011; 45:245-252.
Advisory Board member of RegLink Associates LLC (http://www.reglinkassociates.com)
Member of DIA's Advisory Council for North America
Specialties: global clinical trial disclosure and transparency, regulatory policy, regulatory intelligence